EC Number   |
Activating Compound |
Reference |
|---|
   3.4.21.B10 | 2'-deoxy-5-azacytidine |
can reactivate KLK6 in non-expressing breast cancer cells. Induces KLK6 expression in cell lines MDA-MB-435P, BT-474, MCF-7, and ZR-75-1 and significantly increases synthesis of hK6 protein. Results in a 2fold increase in KLK6 mRNA and protein levels in HMECs. Combined 5-aza-29-deoxycytidine/trichostatin A treatment results in synergistic activation of KLK6 in MDA-MB-231 cells |
678526 |
| 3.4.21.B10 | androgens |
slight up-regulation |
647332 |
| 3.4.21.B10 | caveolin-1 |
mediates both KLK6 gene expression and protein secretion |
682096 |
| 3.4.21.B10 | chondroitin sulfate |
activates hK6 in a concentration-dependent manner |
680699 |
| 3.4.21.B10 | dermatan sulfate |
activates hK6 in a concentration-dependent manner |
680699 |
| 3.4.21.B10 | EB1089 |
vitamin D3 analog EB1089 can restore KLK6 expression in T47D cells |
678526 |
| 3.4.21.B10 | estrogen |
up-regulaion |
647332 |
| 3.4.21.B10 | heparan sulfate |
activates hK6 in a concentration-dependent manner |
680699 |
| 3.4.21.B10 | heparin |
activates hK6 in a concentration-dependent manner |
680699 |
| 3.4.21.B10 | more |
expression of protease M is increased in GST-pi-positive oligodendrocytes during remyelination. After tumor necrosis factor-alpha and IFN-gamma stimulation colocalization of protease M and myelin basic protein in the oligodendroglial process |
682129 |
